Sjogren’s syndrome Market to Surpass US$ 308.4 Mn by 2030

The Global Sjogren’s Syndrome Market, by Drug (Antimalarial Quinolines, Cholinergic Agonists, Corticosteroids and Others (Pain Relief Medication and late phase drug)), by type (Primary and Secondary), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 234.6 million in 2022 and expected to exhibit a CAGR of 3.5% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing research and development of drug for the treatment of sjogren’s syndrome is expected to witness significant growth of the market over the forecast period. For instance, in January 2022, RemeGen Co., Ltd., a biotechnology company announced a positive result of completion of its phase 2 trial of Telitacicept for the treatment of primary sjögren's syndrome in china.

Furthermore, in February 2022, Dompé farmaceutici S.p.A., a pharmaceutical company has announced that the first patient has been enrolled in its Phase 3 clinical trial to evaluate the efficacy and safety of cenegermin for the treatment of severe Sjögren's-related dry eye disease.

Global xx Sjogren’s syndrome Market – COVID-19 Impact (Economic Impact)

The COVID-19 pandemic and lockdown in various countries had a negative impact on the economy of the private healthcare sector.

This lockdown resulted in the closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of pharmaceutical products.

Thus, COVID-19 pandemic has affected the economy in three main ways:

• By directly affecting the production and demand
• By creating disruptions in distribution channels

Supply chain and manufacturing activities in the U.S., Asia Pacific, Europe, and other regions had been disrupted due to lockdowns.

Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources, which are required to ensure safety in hospitals and provide treatment to patients with other diseases, which had also impacted the overall healthcare market negatively.

One of the biggest challenges is supplying the raw materials required to manufacture drugs was the irregularities in the transportation system. Additionally, due to the increasing number of patients suffering from COVID-19 and other life-threatening illnesses, COVID-19 drug product distributors witnessed increasing demand for COVID-19 drug products from retailers.

Browse 35 Market Data Tables and 31 Figures spread through 165 Pages and in-depth TOC on “Sjogren’s Syndrome Market”- Global Forecast to 2022, by Drug (Antimalarial Quinolines, Cholinergic Agonists, Corticosteroids and Others (Pain Relief Medication and late phase drug)), by type (Primary and Secondary), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Sjogren’s Syndrome Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/sjogrens-syndrome-market-5210

Key Takeaways of the Global Sjogren’s Syndrome Market:

• The global sjogren’s syndrome market is expected to exhibit a CAGR of 3.5% over the forecast period, owing to increasing acquisition by key players. For instance, in 2019, ADVANZ PHARMA Corp., a pharmaceutical company acquired the rights of established medicine Salagen (pilocarpine hydrochloride) for the treatment of symptoms of dry mouth in patients with Sjogren’s syndrome.
• Among distribution channel, the Hospital pharmacy segment is expected to account for the largest market share in 2021, this is owing to the fact that majority of sjogren’s syndrome patients are hospitalized for treatment and drugs are sold by hospital pharmacies.
• Key players operating in the global sjogren’s syndrome market include ADVANZ Pharma, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Novartis/MorphoSys, RemeGen, Resolve Therapeutics, TearSolutions, VIELABIO, Otsuka Pharmaceutical Co., Ltd., and Bridge Pharma Inc.